COVINA, Calif., Feb. 21, 2013 /PRNewswire/ -- StemCyte, Inc. proudly announces the endorsement of World and Olympic Champion United States gymnast, ovarian cancer survivor and mother, Shannon Miller. Shannon and her husband chose StemCyte to bank their first child Rocco's umbilical cord blood stem cells, and they are once again turning to StemCyte as they anticipate the arrival of their second child, this summer.
Cord blood stem cells are potential cures for over 80 illnesses, including cancers, blood disorders, immune and genetic diseases, and they continue be a key focus in regenerative medicine research efforts. StemCyte continues to educate expectant parents about the value of banking their child's umbilical cord blood stem cells and are pleased to have Shannon's name added to the growing list of inspirational individuals, who assist in this worthwhile endeavor.
"My role as a parent is second to none in my life. As a mother, athlete and cancer survivor, I realize making smart, healthy choices in life makes all the difference. My husband and I knew banking our son, Rocco's, cord blood was the right decision, and we know it's the right decision for our second child," said Shannon Miller. "StemCyte is the gold standard among cord blood banks, and the clear choice for us once again."
"First and foremost, we want to congratulate Shannon on her victory over cancer and the news of her pregnancy. We are so very proud to have Shannon, a true champion in sports and life, choose our services again," said Calvin Cole, President, Commercial Operations North America. "Shannon reinforces the value of a healthy, educated approach to life and the future of family. StemCyte's and Shannon's values are a perfect match. Together, our mission is to educate expectant parents to support their family's health by storing life-giving umbilical cord stem cells in case they are needed to help fight serious illness in the future."
About StemCyte, Inc.
Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1,800 cord blood units to treat over 80 life-threatening diseases in over 300 transplant centers worldwide. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies, supporting the largest clinical study for using unrelated cord blood transplantation for Thalassemia, one of the most common genetic diseases in the world, and the development of trials investigating regenerative spinal cord therapies. StemCyte is one of the only for-profit companies contracted by the US Department of HHS to help contribute clinical grade cord blood units to the public National Cord Blood Inventory for unrelated transplants. Its headquarters are in Covina, California. To learn more visit www.StemCyte.com.
SOURCE StemCyte, Inc.